The US National Institute of Allergy and Infectious Diseases (NIAID) is launching a trial of a human vaccine for the A-H2N3 influenza virus. The initiative suggests renewed concerns around the potential transmissibility of H2N3 to humans and, more generally, the need for tighter ...
Please Login to read the full article.
